Molecular Chaperone Therapy

📖 Wiki Page

therapeutic1043 wordssynced 2026-04-02

Molecular Chaperone Therapy

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Molecular Chaperone Therapy</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Protein homeostasis</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Misfolded proteins</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Protein folding assistance</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>AD, PD, HD, ALS, Prion diseases</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Aβ metal chelation</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Autophagy induction</td>
</tr>
<tr>
<td class="label">TUDCA</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">Geldanamycin</td>
<td>Hsp90 inhibition</td>
</tr>
<tr>
<td class="label">17-AAG</td>
<td>Hsp90 inhibition</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">NCT01739348</td>
<td>Clioquinol</td>
</tr>
<tr>
<td class="label">NCT03911128</td>
<td>Trehalose</td>
</tr>
<tr>
<td class="label">NCT03854045</td>
<td>TUDCA</td>
</tr>
<tr>
<td class="label">NCT04003116</td>
<td>Bavachinin</td>
</tr>
</table>

...

Molecular Chaperone Therapy

Introduction

Molecular Chaperone Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Molecular chaperones are proteins that assist in the proper folding, assembly, and stabilization of other proteins. In neurodegenerative diseases, pathological proteins ([Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein), [huntingtin](/genes/htt), TDP-43) misfold and aggregate, leading to cellular dysfunction and death.

Molecular chaperone therapy aims to:

Prevent protein misfolding

Enhance proper protein refolding

Facilitate clearance of misfolded proteins

Protect [neurons](/entities/neurons) from proteotoxic stress

Mechanism of Action

Direct Chaperone Activity

Hsp90 Inhibitors

Hsp90 is a major chaperone protein
Inhibitors shift equilibrium toward Hsp70
Enhance degradation of misfolded proteins
Examples: Geldanamycin, 17-AAG (Tanespimycin), 17-DMAG (Alvespimycin)

Hsp70 Inducers

Increase expression of endogenous Hsp70
Enhance protein quality control
Examples: 2-phenylethynesulfonamide (PES), Geranylgeranylacetone

Small Molecule Chaperones

Bind to misfolded proteins
Stabilize native conformation
Examples: Trehalose, Tauroursodeoxycholic acid (TUDCA)

Co-chaperone Modulation

Hsp40 (DNAJ Family)

Cochaperones that recruit clients to Hsp70
Modulate substrate specificity
Target for therapeutic development

Hsp110 Family

Nucleotide exchange factors
Critical for Hsp70 function
Emerging therapeutic targets

Clinical Applications

Alzheimer's Disease

Amyloid-β Chaperones

Anti-aggregation peptides
Small molecules preventing [Aβ](/proteins/amyloid-beta) oligomerization
Examples: Clioquinol, Ladostigil

[Tau](/proteins/tau) Chaperones

Hsp90 inhibitors reduce tau phosphorylation
Hsp70 inducers enhance tau clearance
Combination approaches in development

Parkinson's Disease

α-Synuclein Chaperones

Hsp70 family members (HspA1A, HspA8)
Hsp90 inhibitors reduce aggregation
[Autophagy](/entities/autophagy) enhancement via chaperones

LRRK2 Modulation

Hsp90-LRRK2 interaction
G2019S mutant stabilization by Hsp90
Hsp90 inhibitors for LRRK2 PD

Huntington's Disease

Mutant [Huntingtin](/proteins/huntingtin-protein) (mHTT)

Hsp70 and Hsp40 reduce aggregation
Hsp90 inhibitors enhance clearance
Trehalose as oral chaperone

Autophagy Enhancement

Chaperone-mediated autophagy (CMA)
LAMP-2A modulation
Heat shock protein activation

ALS

SOD1 Mutants

Hsp90 inhibitors stabilize mutant SOD1
Hsp70 enhances degradation
Hsp110 cooperation

[TDP-43](/proteins/tdp-43) Pathology

Hsp90 in [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregation
Cochaperone targeting
Autophagy enhancement

Prion Diseases

PrP^Sc Targeting

Hsp70 family involvement
Hsp90 and PrP conversion
Anti-prion compound screening

Pharmacological Chaperones

Clinical Trials

Combination Approaches

Chaperone + Immunotherapy

Chaperones reduce aggregation
Antibodies clear existing aggregates
Synergistic effect

Chaperone + Autophagy Inducers

Enhanced clearance mechanisms
Reduced proteotoxic load
Multi-target approach

Chaperone + Antioxidants

Oxidative stress reduction
Protein protection
Mitochondrial function support

Adverse Effects

Common

Gastrointestinal disturbances
Headache
Fatigue
Mild liver enzyme elevation

Hsp90 Inhibitors Specific

Heat shock response activation
Protein synthesis inhibition
Potential hepatotoxicity
Cardiac effects (long-term)

Future Directions

Targeted Delivery

Brain-penetrant chaperones
Antibody-chaperone conjugates
Nanoparticle delivery

Gene Therapy

AAV-delivered chaperone genes
Enhanced Hsp70 expression
Controlled expression systems

Precision Medicine

Patient-specific proteinopathies
Genetic mutation targeting
Individualized chaperone cocktails

External Links

[Nature Reviews - Molecular Chaperones](https://www.nature.com)
[Alzheimer's Association - Clinical Trials](https://www.alz.org)
[Michael J. Fox Foundation - PD Research](https://www.michaeljfox.org)

Background

The study of Molecular Chaperone Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[1] Hartl, F.U. & Hayer-Hartl, M. (2009). Molecular chaperones in protein folding. Science, 323(5914), 842-846.

[2] Balch, W.E. et al. (2008). Adapting proteostasis for disease intervention. Science, 319(5865), 916-919.

[3] Muchowski, P.J. & Wacker, J.L. (2005). Modulation of neurodegeneration by molecular chaperones. Nature Reviews Neuroscience, 6(1), 11-22.

[4] Tamaki, Y. et al. (2020). Hsp90 inhibitors for neurodegenerative diseases. Journal of Neurochemistry, 155(2), 153-168.

[5] Chen, X. et al. (2019). Trehalose in neurodegenerative diseases. Autophagy, 15(9), 1641-1653.

[6] Outeiro, T.F. et al. (2021). Molecular chaperones in Parkinson's disease. Brain, 144(7), 2021-2034.

[7] Yerbury, J.J. et al. (2022). The extracellular chaperone clusterin. Trends in Biochemical Sciences, 47(3), 244-256.

[8] Klaips, C.L. et al. (2018). Cellular proteostasis in neurodegeneration. Molecular Cell, 71(5), 729-743.

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — 0.71 · Target: HSPA1A
[Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — 0.67 · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Proteostasis Enhancement via APOE Chaperone Targeting](/hypothesis/h-5d943bfc) — 0.70 · Target: HSPA1A
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Molecular Chaperone Therapy

Molecular Chaperone Therapy

Introduction

Molecular Chaperone Therapy

Introduction

Overview

Mechanism of Action

Direct Chaperone Activity

Co-chaperone Modulation

Clinical Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

ALS

Prion Diseases

Pharmacological Chaperones

Clinical Trials

Combination Approaches

Chaperone + Immunotherapy

Chaperone + Autophagy Inducers

Chaperone + Antioxidants

Adverse Effects

Common

Hsp90 Inhibitors Specific

Future Directions

Targeted Delivery

Gene Therapy

Precision Medicine

See Also

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses